Eye Health Advancements and Ongoing Challenges in Africa

By Crystal Lubbe

October 15, 2024

The article titled “Promising progress on eye health in the African region, but challenges remain” from the World Health Organization (WHO) Regional Office for Africa highlights several key points regarding the current state of eye health in the African region. While there has been notable progress in eye health, significant challenges remain that hinder further advancements.

Progress Made

Despite significant challenges, progress has been made in integrating eye health into primary health care services in African countries. The WHO has recorded a decrease in vision loss due to Vitamin A deficiency, onchocerciasis, and trachoma. These gains are critical for improving overall well-being and reducing the economic burden associated with preventable vision loss.

Challenges

A dire shortage of financial resources and the concentration of scarce human resources in urban areas continue to hinder eye health progress. This results in low community awareness and inadequate access to eye care services. Only 14% of people who need cataract surgery receive it, while more than 80% of those with shortsightedness do not receive treatment. This is in stark contrast to other regions like North America, Australasia, Western Europe, and the Asia-Pacific, where the figures are lower than 10%. The global estimated costs of uncorrected refractive errors and cataracts are significant, amounting to US$14.3 billion annually.

Emerging Challenges

There is a rising trend of eye health challenges related to aging populations, unhealthy lifestyles, and noncommunicable diseases such as diabetic retinopathy and age-related macular degeneration.

WHO’s Current Focus and Initiatives

The WHO is actively supporting countries to integrate eye health services at the primary care level as part of universal health coverage. This includes providing technical support to countries like Ethiopia, Ghana, Niger, Nigeria, Somalia, and Zambia through national situational analyses, strategic plans, and monitoring frameworks. The SPECS 2030 initiative aims to increase the number of people with access to appropriate spectacles, targeting an effective coverage of refractive error (eREC) of 40% by 2030. Liberia and Mozambique have begun implementing this initiative. Furthermore, the WHO has launched a free self-assessment tool called WHOeyes to promote healthy habits and raise eye care awareness. This tool is available in multiple languages and helps check visual acuity while providing educational messaging.

Economic and Social Impact

Good vision significantly impacts overall well-being, academic achievements, and economic growth. Therefore, addressing eye health challenges is crucial for broader societal benefits.

In summary, while there has been progress in reducing certain causes of blindness in Africa, significant challenges persist, including financial and human resource constraints, low community awareness, and emerging eye health issues related to noncommunicable diseases. The WHO is committed to addressing these challenges through various initiatives and support programs aimed at improving eye health in the African region.

Reference url

Recent Posts

bioelectronic medicine innovations
     

Bioelectronic Medicine Innovations: Advancing Non-Invasive Neuromodulation Strategies

🌟 *Ready to explore the future of medicine?*
The new frontier of bioelectronic innovations is reshaping how we approach health. With advancements in non-invasive closed-loop systems, we can personalize treatments and improve patient outcomes without the need for surgical procedures. Discover the groundbreaking potential of autonomic neuromodulation in tackling chronic health conditions in our latest article.

#SyenzaNews #HealthcareInnovation #DigitalHealth #PrecisionMedicine

cervical cancer burden
       

Cervical Cancer Burden: Global Trends and Future Projections

💡 Did you know cervical cancer accounted for 662,044 new cases globally in 2022?

This article jumps into the sobering statistics of cervical cancer, highlighting the stark disparities in incidence and mortality rates tied to human development indexes.

With projections suggesting a dramatic rise in cases by 2050, the urgency for enhanced preventive measures has never been clearer.

Read more about the crucial steps we need to take to combat this growing health issue.

#SyenzaNews #globalhealth #HealthEconomics

datopotamab deruxtecan approval
   

FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

💡 *What does the FDA’s latest approval mean for patients with advanced breast cancer?*
Datopotamab deruxtecan (Datroway) has just been approved for treating unresectable or metastatic HR-positive, HER2-negative breast cancer, offering new hope for patients who have already undergone multiple therapies. This breakthrough, stemming from the TROPION-Breast01 trial, showcases significant improvements in progression-free survival rates—a vital advancement in cancer care.

Curious about the implications of this treatment for both healthcare providers and patients? Dive into the full article to learn more!

#SyenzaNews #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.